Resistant hypertension is common among patients with type 2 diabetes, and is strongly associated with microvascular disease.
In this edition of Clinical Forum, we asked 3 Cardiology Review editorial board members to comment on the role of renal denervation following the publication of the SYMPLICITY HTN-3 trial results.
In their recent article published in the Journal of the American College of Cardiology, Vivek Y. Reddy, MD, and Jeffrey W. Olin, DO, noted “there are few areas in medicine that have gained as much prominence as quickly, or have been as widely dismissed as quickly, as catheter-based renal sympathetic denervation for the treatment of resistant hypertension.
The quest for a non-pharmaceutical therapy for hypertension suffered a setback recently with the publication of two studies on renal denervation (RDN).
Both articles appeared in the Journal of the American College of Cardiology, and both reported on trials that showed the procedure did not lower blood pressure.
But in an accompanying editorial, Vivek Reddy, MD, and Jeffrey Olin, DO, said they have critical questions about those studies that need to be answered before RDN therapy is written off.
Contrave (naltrexone hydrochloride and bupropion hydrochloride extended-release tablets) is a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity.
Renal denervation does not reduce ambulatory blood pressure in patients with resistant hypertension, and denervation procedures may miss targets, according to two studies published online Sept. 8 in the Journal of the American College of Cardiology.